SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Desitin Arzneimittel GmbH
• Treatments: Dopamine; Dopamine Agonists; Piribedil

Criteria

Inclusion Criteria:

• Male and female patients 18 years and older.

• Indication: Morbus Parkinson.

• Treatment with piribedil for the first time.

• Monotherapy with piribedil.

• Combination therapy with L-Dopa (from the beginning or secondary in combination with other antiparkinsonian drugs).

Exclusion Criteria: